Evidence map›Paper›PMID 35121988›Full record

ArticleNature cancer2022

Pharmacological disruption of the MTDH-SND1 complex enhances tumor antigen presentation and synergizes with anti-PD-1 therapy in metastatic breast cancer.

Minhong Shen, Heath A Smith, Yong Wei, Yi-Zhou Jiang, Sheng Zhao, Nicole Wang, Michelle Rowicki, Yong Tang, Xiang Hang, Songyang Wu and 3 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 1 pooled it
8.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 1 synthesis or guideline pooled it, 76 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. mActa pharmaceutica Sinica. B · 2025
    Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 2 countries.

Minhong ShenDepartment of Molecular Biology, Princeton University, Princeton, NJ, USA.
Heath A SmithDepartment of Molecular Biology, Princeton University, Princeton, NJ, USA.
Yong WeiDepartment of Molecular Biology, Princeton University, Princeton, NJ, USA.ORCID http://orcid.org/0000-0002-1034-649X
Yi-Zhou JiangKey Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China.
Sheng ZhaoKey Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China.
Nicole WangDepartment of Molecular Biology, Princeton University, Princeton, NJ, USA.
Michelle RowickiDepartment of Molecular Biology, Princeton University, Princeton, NJ, USA.
Yong TangDepartment of Molecular Biology, Princeton University, Princeton, NJ, USA.
Xiang HangDepartment of Molecular Biology, Princeton University, Princeton, NJ, USA.
Songyang WuKey Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China.
Liling WanDepartment of Molecular Biology, Princeton University, Princeton, NJ, USA.
Zhi-Ming ShaoKey Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China.
Yibin KangDepartment of Molecular Biology, Princeton University, Princeton, NJ, USA. ykang@princeton.edu.ORCID http://orcid.org/0000-0002-1626-6730
Princeton University · USFudan University Shanghai Cancer Center · CN

Funding

TRANSCRIPTIONAL PROFILINGP30CA072720 · NCI · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI Tracie Saunders · 1997 to 2026
$94.5M
Metadherin in Metastasis and Chemoresistance of Breast CancerR01CA134519 · NCI · PRINCETON UNIVERSITY · PI KANG, YIBIN · 2008 to 2012
$1.6M
NCI NIH HHS P30 CA072720NCI NIH HHS R01 CA134519
6 · The paper itself

Abstract

Despite increased overall survival rates, curative options for metastatic breast cancer remain limited. We have previously shown that metadherin (MTDH) is frequently overexpressed in poor prognosis breast cancer, where it promotes metastasis and therapy resistance through its interaction with staphylococcal nuclease domain-containing 1 (SND1). Through genetic and pharmacological targeting of the MTDH-SND1 interaction, we reveal a key role for this complex in suppressing antitumor T cell responses in breast cancer. The MTDH-SND1 complex reduces tumor antigen presentation and inhibits T cell infiltration and activation by binding to and destabilizing Tap1/2 messenger RNAs, which encode key components of the antigen-presentation machinery. Following small-molecule compound C26-A6 treatment to disrupt the MTDH-SND1 complex, we showed enhanced immune surveillance and sensitivity to anti-programmed cell death protein 1 therapy in preclinical models of metastatic breast cancer, in support of this combination therapy as a viable approach to increase immune-checkpoint blockade therapy responses in metastatic breast cancer.

Indexed as

Breast NeoplasmsAntigen PresentationEndonucleasesFemaleHumansMembrane ProteinsMicrococcal NucleaseNuclear ProteinsRNA-Binding ProteinsTranscription FactorsEndonucleasesMembrane ProteinsMicrococcal NucleaseMTDH protein, humanNuclear ProteinsRNA-Binding ProteinsSND1 protein, humanTranscription Factors

Identifiers

PMID35121988
PMCPMC8818088
OpenAlexW3214973185

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.